nach oben

Erschienen in:

01.03.2020 | Clinical study

Cardiovascular outcomes with aromatase inhibitors vs tamoxifen

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

According to study results reported in Circulation, treatment of women with breast cancer using aromatase inhibitors (AIs) is associated with an increased risk of adverse cardiovascular outcomes compared with using tamoxifen, particularly heart failure and cardiovascular mortality. …

Khosrow-Khavar F, et al. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. Circulation 141: 549-559, No. 7, 18 Feb 2020. Available from: URL: http://doi.org/10.1161/CIRCULATIONAHA.119.044750 CrossRef

Titel: Cardiovascular outcomes with aromatase inhibitors vs tamoxifen
Publikationsdatum: 01.03.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-75803-7

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Cardiovascular outcomes with aromatase inhibitors vs tamoxifen

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Ipragliflozin

Hydroxychloroquine/methylprednisolone/corticosteroids

Tiagabine

Duloxetine

Immunosuppressants

Cotrimoxazole/prednisone